Snapshot from Sep 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Business corporate guidance

NanoRepro AG issues revenue guidance

Analysis based on 7 articles · First reported Sep 03, 2026 · Last updated Sep 07, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The revenue guidance provides greater visibility into NanoRepro's growth trajectory, supporting a positive outlook and reinforcing the BUY rating from NuWays AG. The announcement is likely to have a modest positive impact on NanoRepro's share price, reflecting confidence in the company's medium-term growth and M&A optionality.

Health care Biotechnology

NanoRepro, a German multi-brand consumer health platform, published short-, medium-, and long-term revenue guidance ahead of its annual general meeting. The company guided for approximately EUR 18 million in revenue for fiscal year 2026, implying double-digit growth of about 12.5% year-over-year, slightly below analyst expectations. For fiscal year 2028, management targets around EUR 28 million in revenue, and for fiscal year 2030, approximately EUR 40 million, implying a strong compound annual growth rate of about 20% from fiscal year 2025. The guidance reflects both organic growth and potential future acquisitions, supported by a proposal to increase authorized capital by EUR 1.9 million to EUR 7.1 million, which would allow shares to be issued as acquisition consideration. NuWays AG, the covering research firm, reiterated its BUY rating with a target price of EUR 4.40, adjusting its revenue forecasts to align with the new guidance. The company also recently completed the acquisition of the remaining 67% stake in Hyped About Science GmbH, which will be renamed Alphabiol GmbH, consolidating its nutritional elixirs brand as a third pillar alongside rapid testing kits and PAEDIPROTECT.

80 NanoRepro published revenue guidance
60 NanoRepro seeking shareholder approval
50 NuWays AG reiterated BUY rating NanoRepro
stock
NanoRepro is the subject of the guidance and acquisition, positioning itself for growth with a multi-brand strategy and potential M&A.
Importance 100.0 Sentiment 60.0
priv
Hyped About Science GmbH was fully acquired by NanoRepro and will be renamed Alphabiol GmbH, becoming a dedicated vehicle for the ALPHABIOL brand.
Importance 50.0 Sentiment 40.0
priv
Alphabiol GmbH, the renamed entity, will house the ALPHABIOL nutritional elixirs brand, forming a third pillar of NanoRepro's business.
Importance 50.0 Sentiment 40.0
priv
NuWays AG, as the covering research firm, reiterated its BUY rating and adjusted forecasts, reflecting its analysis of NanoRepro's guidance.
Importance 40.0 Sentiment 20.0
priv
Terraplasma GmbH received the Phlas brand and associated products as part of the transaction, exiting its co-ownership of hyped about science.
Importance 20.0 Sentiment 10.0
per
Mike Eckel, incoming CFO, is expected to lead finance and back-office harmonization from Q4 2026, supporting margin improvements.
Importance 10.0 Sentiment 10.0
per
Sarah Hellemann, the analyst at NuWays AG, authored the research reports and reiterated the BUY rating.
Importance 10.0 Sentiment 10.0
curr
The European Union — Euro is the currency in which NanoRepro's revenue guidance and financial figures are denominated.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.